Heart rhythm mystery: new study maps hidden triggers of persistent AF

NCT ID NCT04041778

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study looked at 17 adults with persistent atrial fibrillation (a long-lasting heart rhythm problem) to find specific areas in the heart that may keep the condition going. Researchers used special mapping to identify stable high-frequency electrical signals. The goal was to better understand what causes persistent AF, so future treatments can be more effective.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

17 people

The number who actually took part.

Started

Jul 2019

Finished

Sep 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients will have been diagnosed with Persistent Atrial Fibrillation (persAF). They will have been listed for a first time persAF ablation as part of standard routine care.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Must be aged 18 years or over * Must be able to communicate in written and spoken English * Must be able to give signed informed consent. * All patients must be defined as having persistent atrial fibrillation (AF \> 7 days) and must be in AF at the start of the procedure. * The patient preferably should be undergoing AF ablation for the first time, however repeat ablations can be permitted. * The patient must be listed for persistent AF ablation as part of standard clinical care. Exclusion Criteria: * Symptoms secondary to ischaemic or valvular heart disease * Congenital heart disease * Previous history of a cardiac arrhythmia (other than AF, atrial tachycardia, atrial flutter). * Previous cardiothoracic surgery * Underlying severe respiratory disease (i.e. patient on long term oxygen therapy) * Medical conditions which will affect cardiac rhythm, even if treated (e.g. thyroxine, etc.) * Presence of chest deformity. * Left atrial dilatation (L or R atrial end-diastolic dimension \> 4.5cm in any conventional plane of measurement on 2D transthoracic echocardiography). * Presence of implantable cardiac defibrillator or pacemaker (including cardiac resynchronisation devices).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrial fibrillation mechanisms are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University Hospitals Leicester NHS Foundation Trust, Glenfield Hospital

    Leicester, LE3 9QP, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.